A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

Trial Identifier: 4482-023
Sponsor: MSD
Start Date: December 2024
Primary Completion Date: January 2031
Study Completion Date: January 2031
Condition: Coronavirus Infection

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary

Trial Locations

Country Location
Taiwan, Kaohsiung Kaoshiung, Kaohsiung, Taiwan, 807
United States, AZ Phoenix, AZ, United States, 85051
United States, CA Northridge, CA, United States, 91325
United States, CA San Diego, CA, United States, 91208
United States, CA San Francisco, CA, United States, 94102
United States, CA Westlake Village, CA, United States, 91361
United States, CO Wheat Ridge, CO, United States, 80033
United States, FL Hialeah, FL, United States, 33012
United States, FL Loxahatchee, FL, United States, 33470
United States, FL Miami, FL, United States, 33125
United States, FL Tampa, FL, United States, 33614
United States, FL Tampa, FL, United States, 33603
United States, FL Weston, FL, United States, 33331
United States, GA Lawrenceville, GA, United States, 30046
United States, GA Snellville, GA, United States, 30078
United States, GA Union City, GA, United States, 30291
United States, ID Boise, ID, United States, 83709
United States, LA NATCHITOCHES, LA, United States, 71457
United States, MI Farmington Hills, MI, United States, 48334
United States, MS Fayette, MS, United States, 39069
United States, MS Ridgeland, MS, United States, 39157
United States, NC Monroe, NC, United States, 28112
United States, NC Mount Airy, NC, United States, 27030
United States, PR Humacao, PR, United States, 00791
United States, TN Jackson, TN, United States, 38305
United States, TX Pearland, TX, United States, 77584